Lipocine announces publication and discussion of lpcn 1148 manuscript at the liver meeting 2024 editor's cut session

Salt lake city , nov. 18, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript "oral lpcn 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: a randomized, placebo-controlled phase 2 trial" in the journal hepatology and discussion at the liver meeting (aasld) 2024 editor's cut: clinical study session held on november 16, 2024. lpcn 1148 is targeted to be a "first in class" product candidate with a novel mechanism of action for overt hepatic encephalopathy and sarcopenia indications.
LPCN Ratings Summary
LPCN Quant Ranking